Lexeo Therapeutics (LXEO) Non Operating Income (2022 - 2026)
Lexeo Therapeutics recorded quarterly Non Operating Income of -$1000.0 in Q1 2026, down 100.05% quarter-over-quarter from $2.2 million in Q4 2025, and up 75.0% year-over-year from -$571.43 in Q1 2025.
Lexeo Therapeutics' Non Operating Income history runs 5 years deep, the most recent figure standing at -$1000.0 for Q1 2026.
- In Q1 2026, Non Operating Income rose 75.0% year-over-year to -$1000.0; the TTM figure through Mar 2026 stood at $6.8 million (up 84750.0% YoY), while the FY2025 annual figure was $9.3 million, up 103388.89% from the prior year.
- Non Operating Income came in at -$1000.0 for Q1 2026 at Lexeo Therapeutics, down from $2.2 million in the prior quarter.
- In the past five years, Non Operating Income ranged from a high of $4.6 million in Q2 2025 to a low of -$614000.0 in Q4 2022.
- A 5-year average of $480214.3 and a median of -$3000.0 in 2023 frame the typical range for Non Operating Income.
- On a YoY basis, Non Operating Income climbed as much as 458600.0% in 2025 and fell as far as 200.0% in 2025.
- Lexeo Therapeutics' Non Operating Income stood at -$614000.0 in 2022, then surged by 98.86% to -$7000.0 in 2023, then soared by 57.14% to -$3000.0 in 2024, then soared by 73333.33% to $2.2 million in 2025, then sank by 100.05% to -$1000.0 in 2026.
- According to Business Quant data, Non Operating Income over the past three periods registered -$1000.0, $2.2 million, and -$9000.0 for Q1 2026, Q4 2025, and Q3 2025 respectively.
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Non Op. Inc. (Qtr) |
|---|---|---|---|---|---|
| 1 | Quantum Biopharma | 961,148.99 Bn | 961,148.98 Bn | - | - |
| 2 | Alterity Therapeutics | 744,933.29 Bn | 744,933.26 Bn | - | - |
| 3 | Legend Biotech | 2,540.00 Bn | 2,539.71 Bn | 242.10 Mn | - |
| 4 | Nanobiotix | 2,199.85 Bn | 2,199.78 Bn | - | - |
| 5 | Akari Therapeutics | 1,635.88 Bn | 1,635.88 Bn | - | 444,000.00 |
| 6 | Vertex Pharmaceuticals | 111.32 Bn | 104.07 Bn | 2.59 Bn | - |
| 7 | Evaxion A | 62.56 Bn | 62.54 Bn | - | - |
| 8 | Regeneron Pharmaceuticals | 62.55 Bn | 53.79 Bn | 3.31 Bn | 201.20 Mn |
| 9 | Alnylam Pharmaceuticals | 39.57 Bn | 36.56 Bn | 959.66 Mn | -46.98 Mn |
| 10 | Lexeo Therapeutics | 392.12 Mn | 199.07 Mn | - | -1,000.00 |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | -1,000.00 |
| Dec 31, 2025 | 2.20 Mn |
| Sep 30, 2025 | -9,000.00 |
| Jun 30, 2025 | 4.59 Mn |
| Mar 31, 2025 | -4,000.00 |
| Sep 30, 2024 | -3,000.00 |
| Jun 30, 2024 | -1,000.00 |
| Mar 31, 2024 | -5,000.00 |
| Dec 31, 2023 | -7,000.00 |
| Sep 30, 2023 | 165,000.00 |
| Jun 30, 2023 | -3,000.00 |
| Mar 31, 2023 | -4,000.00 |
| Dec 31, 2022 | -614,000.00 |
| Sep 30, 2022 | 427,000.00 |